Anti-reflux mucosal ablation (ARMA) as a novel minimally invasive treatment for severe gastroesophageal reflux disease in a child: the first pediatric case report
By
Jonas Povilavičius
Geistė Tubutytė
Kamilė Bagdonaitė
Audrius Dulskas
Arūnas Strumila
Austėja Račytė
June 1, 2026
Clinical Scorecard: Minimally Invasive Anti-Reflux Mucosal Ablation (ARMA) for Severe Gastroesophageal Reflux Disease: A Pediatric Case Study
At a Glance
Category Detail
Condition Gastroesophageal Reflux Disease (GERD) Key Mechanisms Minimally invasive endoscopic technique using targeted mucosal ablation to enhance the anti-reflux barrier. Target Population Pediatric patients, particularly those with neurological impairments and refractory GERD. Care Setting Endoscopic procedure performed under general anesthesia.
Key Highlights
ARMA is a novel technique for treating refractory GERD in pediatric patients. The procedure was performed without intra-procedural complications. Significant improvement in reflux control and tolerance of gastrostomy feeding observed post-procedure. No immediate adverse events or respiratory deterioration noted. First report of ARMA application in a neurologically impaired child. Guideline-Based Recommendations
Diagnosis
Consider differential diagnoses including neurogenic dysphagia and gastroparesis-related regurgitation. Management
ARMA is recommended for high-risk patients with medication-refractory GERD. Monitoring & Follow-up
Follow-up endoscopy to assess improvement in gastroesophageal flap valve competence. Risks
High risk of treatment failure and complications in neurologically impaired patients. Patient & Prescribing Data
Neurologically impaired children with severe, medication-refractory GERD.
ARMA may reduce reliance on acid-suppressive therapy and improve quality of life.
Clinical Best Practices
Utilize a multidisciplinary team approach for high-risk patients. Monitor for symptom improvement and complications post-ARMA. Related Resources & Content
